WO1998053812A1 - Inhibitors of naaladase enzyme activity - Google Patents
Inhibitors of naaladase enzyme activity Download PDFInfo
- Publication number
- WO1998053812A1 WO1998053812A1 PCT/US1997/014347 US9714347W WO9853812A1 WO 1998053812 A1 WO1998053812 A1 WO 1998053812A1 US 9714347 W US9714347 W US 9714347W WO 9853812 A1 WO9853812 A1 WO 9853812A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- benzylhydroxyphosphinyl
- pentanedioic
- hydroxyphosphinyl
- pentanedioic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
Definitions
- the present invention relates to novel NAALADase 20 inhibitors and methods of using the same for treating cancer, preventing tumor cell growth, inhibiting prostate tumor cell growth, and inhibiting NAALADase enzyme activity, by administering an effective amount of the NAALADase inhibitor.
- Prostate cancer is the leading form of cancer and the second leading cause of death from cancer for men in the United States.
- the American Cancer Society has estimated that in 1996 alone, 317,100 new cases of prostate cancer were diagnosed and 41,400 deaths were caused by prostate cancer.
- the incidence rate of prostate cancer increased 65% between 1980 and 1990, and will continue to rise with improved screening tests and longer life expectancies. While most men used to die of other illnesses before prostate cancer had a chance to develop, higher prostate cancer mortality rates are expected as men live longer and the disease has more time to progress .
- PSMA Prostate Specific Membrane Antigen
- NAAG and NAALADase have been implicated in several human and animal pathological conditions relating to glutamate abnormalities and neurotoxicity . For example, it has been demonstrated that intra-hippocampal injections of NAAG elicit prolonged seizure activity. More recently, it was reported that rats genetically prone to epileptic seizures have a persistent increase in their basal level of NAALADase activity. These observations lend support the hypothesis that increased availability of synaptic gluta ate elevates seizure susceptibility, and suggest that NAALADase inhibitors may- provide anti-epileptic activity.
- NAAG and NAALADase have also been implicated in the pathogenesis of ALS and in the pathologically similar animal disease called Hereditary Canine Spinal Muscular Atrophy (HCSMA) . It has been shown that concentrations of NAAG and its metabolites -- NAA, glutamate and aspartate -- are elevated two- to three-fold in the cerebrospinal fluid of ALS patients and HCSMA dogs. Additionally, NAALADase activity is significantly increased (two- to three-fold) in post-mortem spinal cord tissue from ALS patients and HCSMA dogs. As such, NAALADase inhibitors might be clinically useful in curbing the progression of ALS if an increased metabolism of NAAG is responsible for the alterations of CSF levels of these acidic amino acids and peptides.
- HCSMA Hereditary Canine Spinal Muscular Atrophy
- NAALADase inhibitors could be useful in treating glutamate abnormalities.
- the present invention is directed to the surprising and unexpected discovery that the novel compounds of the present invention are not only effective NAALADase inhibitors but are effective in treating prostate diseases, particularly prostate cancer.
- the cancer data relate to prostate cancer cells, NAALADase inhibitors are expected to be equally effective in treating cancer of other tissues where NAALADase enzyme reside, such as the brain, kidney and testis.
- NAALADase inhibitors While a few NAALADase inhibitors have been identified, they have only been used in non-clinical research. Examples of such inhibitors include general metallopeptidase inhibitors such as o-phenanthroline, metal chelators such as EGTA and EDTA, and peptide analogs such as quisqualic acid and ⁇ -NAAG. Accordingly, a need exists for more NAALADase inhibitors to be identified and, particularly, for the treatment of prostate diseases such as prostate cancer.
- general metallopeptidase inhibitors such as o-phenanthroline
- metal chelators such as EGTA and EDTA
- peptide analogs such as quisqualic acid and ⁇ -NAAG. Accordingly, a need exists for more NAALADase inhibitors to be identified and, particularly, for the treatment of prostate diseases such as prostate cancer.
- the present invention is directed to novel NAALADase inhibitors and methods of using the same for treating cancer, preventing tumor cell growth, inhibiting prostate tumor cell growth, and inhibiting NAALADase enzyme activity, in an animal, comprising administering an effective amount of the NAALADase inhibitor.
- Preferred NAALADase inhibitors include compounds of formula I:
- R 2 is C x -C 9 straight or branched chain alkyl, C 2 -C 9 - straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar x ;
- R 2 is C x -C 9 straight or branched chain alkyl, C 2 -C 9 - straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar l; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl groups may be optionally substituted with carboxylic acid;
- R 3 and R. are independently hydrogen, straight or branched chain alkyl, C 2 - C 6 straight or branched chain alkenyl, dialkyl, halogen, or Arj_ provided that both R 3 and R 4 are not hydrogen.
- the compound of formula I is present in an amount that is effective for inhibiting NAALADase enzyme activity, or treating a prostate disease in an animal.
- the present invention further relates to a method of inhibiting NAALADase enzyme activity in an animal, comprising administering an effective amount of the compound of formula I to said animal .
- FIG. 1 is a bar graph plotting the growth of the prostate cancer cell line, LNCAP, against various concentrations of quisqualic acid, a NAALADase Inhibitor.
- FIG. 1 shows the effect of 7 -day treatment with quisqualate on the growth of LNCAP cells. Concentrations ranging from 10 nM to 1 ⁇ M of quisqualate show a sharp dose-dependent decrease of LNCAP cell proliferation as indicated by the significant decrease in the incorporation of [3H] thymidine .
- FIG. 2 is a bar graph plotting the growth of the prostate cancer cell line, LNCAP, against various concentrations of 2- (phosphonomethyl) pentanedioic acid, a NAALADase Inhibitor.
- FIG. 2 shows the effect of 7-day treatment with 2- (phosphonomethyl) pentanedioic acid on the growth of LNCAP cells. Concentrations ranging from 100 pM to 10 nM of 2- (phosphonomethyl) pentanedioic acid show a sharp dose-dependent decrease of LNCAP cell proliferation as indicated by the significant decrease in the incorporation of [3H] thymidine .
- FIG. 3 is a line graph of the response of LNCAP human prostate tumors to daily treatment with 2-
- FIG. 4 is a line graph plotting the survival percentage of animals treated with injections against the number of days.
- FIG. 5 is a line graph plotting tumor growth against days following rat dunning cell injections. Cells were injected, over a period of 84 days, with various dosages of 2- (phosphonomethyl) pentanedioic acid and a control vehicle. FIG. 5 shows that tumor growth slowed as a function of 2- (phosphonomethyl) pentanedioic acid dosage.
- FIG. 6 is a line graph of the response of R3327 rat prostate tumors to daily treatment with 2- [[ (phenylmethyl) hydroxyphosphinyl] methyl] pentanedioic acid. Mean of individual tumor volumes expressed relative to the volume at the start of treatment (V/V Q ) are plotted as a function of time. Treatment with 2-
- Compound 3 refers to 2 ⁇ (phosphonomethyl) pentanedioic acid, a NAALADase inhibitor.
- Competitive, uncompetitive and non-competitive inhibition can be distinguished by the effects of an inhibitor on the reaction kinetics of an enzvme .
- Competitive inhibition occurs when the inhibitor combines reversibly with the enzyme in such a way that it competes with a normal substrate for binding at the active site.
- the affinity between the inhibitor and the enzyme may be measured by the inhibitor constant, K i( which is defined as:
- [E] is the concentration of the enzyme
- [I] is the concentration of the inhibitor
- [EI] is the concentration of the enzyme-inhibitor complex formed by the reaction of the enzyme with the inhibitor.
- K ⁇ as used herein refers to the affinity between the inventive compounds and NAALADase.
- IC50 is a related term used to define the concentration or amount of a compound which is required to cause a 50% inhibition of the target enzyme.
- inhibitors in the context of tumor growth or tumor cell growth, may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, among others. In the extreme, complete inhibition, is referred to herein as prevention.
- NAAG refers to N-acetyl-aspartyl-glutamate, an important peptide component of the brain, with levels comparable to the major inhibitor neurotransmitter gamma- aminobutyric acid (GABA) .
- GABA neurotransmitter gamma- aminobutyric acid
- NAAG is neuron-specific, present in synaptic vesicles and released upon neuronal stimulation in several systems presumed to be glutamatergic . Studies suggest that NAAG may function as a neurotransmitter and/or neuromodulator in the central nervous system, or as a precursor of the neurotransmitter glutamate.
- NAALADase refers to N-acetylated ⁇ -linked acidic dipeptidase, a membrane-bound metallopeptidase which catabolizes NAAG to N-acetylaspartate (NAA) and glutamate:
- NAALADase shows a high affinity for NAAG with a Km of 540 nM. If NAAG is a bioactive peptide, then NAALADase may serve to inactivate NAAG'S synaptic action. Alternatively, if NAAG functions as a precursor for glutamate, the primary function of NAALADase may be to regulate synaptic glutamate availability.
- “Pharmaceutically acceptable salt” refers to a salt of the inventive compounds which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable.
- the salt can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate, camphorate, ca phorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate heptanoate, hexanoate, hydro- chloride hydrobromide , hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, thiocyan
- Examples of a base salt include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine and lysine .
- the basic nitrogen-containing groups can be quarternized with agents including lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl , dibutyl and diamyl sulfates; long chain halides such as decyl , lauryl, myristyl and stearyl chlorides, bromides and iodides; and aralkyl halides such as benzyl and phenethyl bromides .
- lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides
- dialkyl sulfates such as dimethyl, diethyl , dibutyl and diamyl sulfates
- long chain halides such as decyl , lauryl, myristyl and ste
- prevention in relation to tumor growth or tumor cell growth, means no tumor or tumor cell growth if none had occurred, no further tumor or tumor cell growth if there had already been growth.
- prostatic disease relates to prostate cancer such as adenocarcinoma or metastatic cancers, conditions characterized by abnormal growth of prostatic epithelial cells such as benign prostatic hyperplasia, and other conditions requiring treatment by the compounds of the present invention.
- PSA refers to Prostate Specific Antigen, a well known prostate cancer marker. It is a protein produced by prostate cells and is frequently present at elevated levels in the blood of men with prostate cancer. PSA correlates with tumor burden, serves as an indicator of metastatic involvement, and provides a parameter for following a prostate cancer patient's response to surgery, irradiation and androgen replacement therapy.
- PSMA Prostate Specific Membrane Antigen
- PSMA Prostate Specific Membrane Antigen
- prostatic ductal epithelium is present in seminal plasma, prostatic fluid and urine. It has been found that the expression of PSMA cDNA confers the activity of NAALADase.
- treatment refers to any process, action, application, therapy, or the like, wherein an animal, including a human being, is subject to medical aid with the object of improving the animal's condition, directly or indirectly.
- the present invention relates to a compound of formula I
- R x is hydrogen, -C,, straight or branched chain alkyl, C 2 - C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or AT J .;
- R 2 is straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar 1# wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, C x -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, dialkyl, halogen, or Ar ⁇ , provided that both R 3 and R 4 are not hydrogen.
- alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl groups other than R 3 and R 4 may be optionally substituted with C 3 -C 8 cycloalkyl, C 3 or C 5 cycloalkyl, C 5 -C, cycloalkenyl, C L -C 4 alkyl, -Q, alkenyl, halo, hydroxy, carboxy, nitro, trifluoromethyl , -C ⁇ straight or branched chain alkyl or alkenyl, C 1 - C i alkoxy, -C, alkenyloxy, phenoxy, benzyloxy, or Ar l; and where Ar ⁇ is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 4-indolyl, 2-furyl, 3-furyl, tetrahydrofuranyl,
- R ⁇ and R 2 groups are either straight or branched aliphatic substituents or carbocyclic substituents illustrated by the compounds selected from the group of formula I :
- R is hydrogen, C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, 1-naphthyl, 2- naphthyl , or phenyl ;
- R 2 is -Cc, straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 3 -C 7 cycloalkenyl, 1-naphthyl, 2- naphthyl, or phenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, 1-naphthyl, 2-naphthyl, or phenyl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, dialkyl , halogen, or Ar x , provided that both R 3 and R 4 are not hydrogen.
- R x is either a straight or branched aliphatic group or a carbocyclic group
- R 2 is ethyl which is substituted with a carboxylic acid
- R is either a straight or branched aliphatic group or a carbocyclic group
- R 2 is ethyl which is substituted with a carboxylic acid
- R ⁇ is a straight or branched aliphatic group or a carbocyclic group
- R 2 is phenyl are selected from the group consisting of:
- R ⁇ is a straight or branched aliphatic group or a carbocyclic group and R 2 is ethyl which is substituted with carboxylic acid
- R ⁇ is a straight or branched aliphatic group or a carbocyclic group and R 2 is an
- C 2 -C 8 alkyl or alkenyl chain which is substituted with a carboxylic acid Exemplary species include:
- hydroxyphosphinyl derivatives wherein R x is benzyl and R 2 is a straight or branched aliphatic group or a carbocyclic group.
- Exemplary species include: 3- (benzylhydroxyphosphinyl) -3 -prop-2-enyl-2-methylpropanoic acid;
- R x is said alkyl, alkenyl, cycloalkyl, or aryl group which is substituted with a heterocyclic group and R 2 is ethyl which is substituted with a carboxylic acid are selected from the group consisting of:
- R is said alkyl, alkenyl, cycloalkyl, or aryl group which is substituted with a heterocyclic group and R 2 is phenyl are selected from the group consisting of :
- Especially preferred methods use compounds wherein Ri is benzyl and R 2 is said alkyl, alkenyl, cycloalkyl, or aryl group which is substituted with a heterocyclic group are selected from the group consisting of:
- R groups are heterocyclic substituents illustrated by the compounds selected from the group having formula I:
- R is C-,-C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar x , wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl or aryl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, straight or branched chain alkyl, C 2 -C 5 straight or branched chain alkenyl, dialkyl, halogen, or Ar x , provided that both R 3 and R 4 are not hydrogen.
- Especially preferred methods use compounds wherein R x is a heterocyclic group and R 2 is ethyl which is substituted with carboxylic acid are selected from the group consisting of: 2- [1- [ (2 -pyridyl) hydroxyphosphinyl] ethyl] pentanedioic acid; 2- [1- [ (3 -pyridyl) hydroxyphosphinyl] propyl] pentanedioic acid; 2- [1- [ (4 -pyridyl) hydroxyphosphinyl] butyl] pentanedioic acid; 2- [1- [ (tetrahydrofuranyl) hydroxyphosphinyl] but -3 -enyl] pentan
- R x is a heterocyclic group and R 2 is phenyl are selected from the group consisting of:
- R is hydrogen, -C;, straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl group, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar x ;
- R 2 is Ar lr wherein said aryl group may be optionally substituted with carboxylic acid;
- R 3 and R 4 are independently hydrogen, straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, dialkyl , halogen, or Ar 17 provided that both R 3 and R 4 are not hydrogen.
- Particular species wherein R 2 is heterocyclic may be easily made and used by persons of ordinary skill in the art in accordance with the teachings provided herein and known in the art .
- R x is benzyl and R 2 is heterocyclic are selected from the group consisting of :
- the compounds of the present invention can be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathways depicted below (see Schemes I -IX) .
- Precursor compounds may be prepared by methods known in the art, such as those described in the method of Jackson et al . (J " . Med. Chem. 39(2), 619-622, Design. Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated a-Linked Acidic Dipeptidase) and, for example, in Froestl et al . ⁇ J. Med. Chem . , 1995, 38, 3313-3331, Phosphinic Acid Analogues of GABA) .
- R' (CH 2 ) 3 Ph H n-C 7 H 15 B. (CH,) 4 Ph I n- ⁇ C 9 H 17 C. (CH,) ⁇ Ph J n- ⁇ C q H, D. (CH 2 ) 4 (P-F-Ph) K n- • C 10 H 2 E . (CH 2 ) 4 - (3 -pyridyl) L CH, ( CH, ) (CH 3 C 4 Hg F. n-C.H, M CH. ( CH, ) CH ( CH,
- R' n-C 4 H Q 0. CH(CH,)C ⁇ H, ⁇
- Scheme IV and Scheme V Another route for preparing the compounds of the present invention is as set forth below in scheme IV and Scheme V.
- Scheme IV and Scheme V also show a phosphinic acid derivative as a starting material to prepare the compounds of the present invention and the R group is contemplated as including any reasonable chemical substitution and includes without limitation the R groups listed in Scheme II and within the specification.
- Scheme IX and Scheme X Another route for preparing the compounds of the present invention is as set forth below in Scheme IX and Scheme X.
- Scheme IX and Scheme X also show a phosphinic acid derivative as a starting material to prepare the compounds of the present invention and the R and R' groups are contemplated as including any reasonable chemical substitution and include without limitation the R groups listed in Scheme II and the R' groups listed in Scheme VIII and within the specification.
- compositions of the Present Invention also relates to a pharmaceutical composition comprising:
- the pharmaceutical composition further comprises a therapeutic agent selected from the group consisting of therapeutic hormones, chemotherapeutic agents, monoclonal antibodies, anti- angiogenesis agents, radiolabelled compounds, antineoplastic agents and mixtures thereof.
- therapeutic hormones include diethylstilbestrol (DES) , leuprolide, flutamide, cyproterone acetate, ketoconazole and amino glutethimide are preferred.
- antineoplastic agents include 5- fluorouracil , vinblastine sulfate, estramustine phosphate, suramin and strontium-89.
- chemotherapeutic agents include buserelin, chlorotranisene, chromic phosphate, cisplatin, cyclophosphamide , dexamethasone , doxorubicin, estradiol, estradiol valerate, estrogens conjugated and esterified, estrone, ethinyl estradiol, floxuridine, goserelm, hydroxyurea, melphalan, methotrexate, mitomycin and prednisone .
- the compound of formula I is present in an amount that is effective for inhibiting NAALADase activity in an animal or treating a prostate disease in an animal .
- a process for preparing a pharmaceutical composi-tion or medicament containing a compound of the present invention for treating a disease is also contemplated.
- the present invention further relates to a method of inhibiting NAALADase enzyme activity in an animal, comprising administering an effective amount of a compound of formula I to said animal .
- the present invention also relates to a method of treating a prostate disease in an animal, comprising administering an effective amount of a compound of formula I to said animal .
- said prostate disease is prostate cancer such as prostatic adenocarcinoma, benign prostatic hyperplasia, or conditions involving the prostate requiring administration of the compounds of the present invention, such prostatic intraepithelial neoplasia (PIN) .
- cancers of the present invention include without limitation: ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain -cancer, - breast cancer, cervix cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T- cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head & neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non- Hodgkin's lymphoma
- the compounds of the present invention are particularly useful in treating cancer of tissues where NAALADase enzymes reside.
- tissues include the prostate as well as the brain, kidney and testis.
- NAALADase inhibitor based drugs are used as an immediate initial therapy prior to surgery and radiation therapy, and as a continuous post -treatment therapy in patients at risk for recurrence or metastasis (based upon high PSA, high Gleason's score, locally extensive disease, and/or pathological evidence of tumor invasion in the surgical specimen) .
- the goal in these patients is to inhibit the growth of potentially metastatic cells from" the primary tumor during surgery or radiotherapy and inhibit the growth of tumor cells from undetectable residual primary tumor.
- NAALADase inhibitor based drugs are used as a continuous supplement to, or possible as a replacement for hormonal ablation. The goal in these patients is to slow tumor cell growth from both the untreated primary tumor and from the existing metastatic lesions.
- the invention may be particularly efficacious during post-surgical recovery, where the present compositions and methods may be particularly effective in lessening the chances of recurrence of a tumor engendered by shed cells that cannot be removed by surgical intervention.
- the present invention also includes a diagnostic kit for performing the methods of the present invention and may contain compounds and/or compositions containing the compounds of the present invention. Radiolabelled compounds and monoclonal antibodies may be used in a manner so as to provide diagnostic information. Examples of diagnostic information and uses include determining the type of disease, the progress of the particular disease, the location of cells targeted by a NAALADase inhibitor, radiolabelled compound or monoclonal antibody, and similar diagnostic uses known to persons skilled in the art .
- the compounds may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneal , intrathecal, intraventricular, intrasternal or intracranial injection and infusion techniques. Invasive techniques are preferred, particularly direct administration to damaged neuronal tissue.
- the compounds of the present invention should readily penetrate the blood-brain barrier when peripherally administered.
- Compounds which cannot penetrate the blood- brain barrier can be effectively administered by an intraventricular route .
- the compounds may also be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparations may also be sterile injectable solutions or suspensions in non- toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1 , 3 -butanediol .
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile fixed oils are conventionally- -employed as solvents or suspending mediums.
- any bland fixed oil such as a synthetic mono- or di-glyceride may be employed.
- Fatty acids such as oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated forms, are useful in the preparation of injectables.
- These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.
- the compounds may be administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate.
- Capsules may contain diluents including lactose and dried corn starch.
- Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient .
- the oral dosage forms may further contain sweetening and/or flavoring and/or coloring agents .
- compositions can be prepared by mixing the drug with suitable non- irritating excipients which are solid at room temperature, but liquid at rectal temperature such that they will melt in the rectum to release the drug.
- suitable non- irritating excipients include cocoa butter, beeswax and polyethylene glycols.
- the compounds may be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin or the lower intestinal tract.
- the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
- the compounds may be formulated into ointments, such as petrolatum.
- suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol , benzyl alcohol and water.
- Topical application to the lower intestinal tract can be effected in rectal suppository formulations (see above) or in suitable enema formulations.
- the compounds of the present invention may be administered by a single dose, multiple discrete doses or continuous infusion. Since the compounds are small, easily diffusible and relatively stable, they are well suited to continuous infusion. Pump means, particularly subcutaneous pump means, are preferred for continuous infusion.
- compositions and methods of the invention also may utilize controlled release technology.
- NAALADase inhibitors may be incorporated into a polymer matrix for controlled release over a period of days.
- Such controlled release films are well known to the art.
- polymers commonly employed for this purpose include nondegradable ethylene-vinyl acetate copolymer and degradable lactic acid-glycolic acid copolymers .
- Certain hydrogels such as poly (hydroxyethylmethacrylate) or poly (vinylalcohol) also may be useful.
- Dosage Dose levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels being about 0.1 mg to about 1,000 mg .
- the specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vi tro dosage-effect results provide useful guidance on the proper doses for patient administration.
- the compounds of the present invention are administered in lyophilized form.
- 1 to 100 mg of a compound of the present invention may be lyophilized in individual vials, together with a carrier and a buffer, such as mannitol and sodium phosphate.
- the compound may be reconstituted in the vials with bacteriostatic water before administration.
- the compounds of the present invention may be administered in combination with one or more therapeutic agents, including chemotherapeutic agents.
- chemotherapeutic agents including chemotherapeutic agents.
- TABLE I provides known median dosages for selected chemotherapeutic agents. Specific dose levels for these agents will depend upon considerations such as those identified above for the compounds of the present invention.
- any administration regimen regulating the timing and sequence of drug delivery can be used and repeated as necessary to effect treatment .
- Such regimen may include pretreatment and/or co- administration with additional therapeutic agents.
- the compounds of the present invention may be administered (i) prior to surgery or radiation treatment to reduce the risk of metastasis; (ii) during surgery or in conjunction with radiation treatment; and/or (iii) after surgery or radiation therapy to reduce the risk of recurrence and to inhibit the growth of any residual tumorous cells .
- the compounds of the present invention may be administered as a continuous supplement to, or as a replacement for, hormonal ablation in order to slow tumor cell growth in both the untreated primary tumor and the existing metastatic lesions.
- the methods of the present invention are particularly useful where shed cells could not be removed by surgical intervention. After post-surgical recovery, the methods of the present invention would be effective in reducing the chances of recurrence of a tumor engendered by such shed cells .
- PSA Prostate Specific Antigen
- Hormonal Therapy Hormonal ablation is the most effective palliative treatment for the 10% of patients with metastatic prostate cancer. Hormonal ablation by medication and/or orchiectomy is used to block hormones that promote further growth and metastasis of prostate cancer. With time, both the primary and metastatic tumors of virtually all of these patients become hormone-independent and resistant to therapy. Approximately 50% of patients with metastatic cancer die within three years after initial diagnosis, and 75% of such patients die within five years after diagnosis. Continuous supplementation with the compounds of the present invention may be used to prevent or reverse this potentially metastasis- permissive state. (iii) Chemotherapy
- the compounds of the present invention may also be used in combination with monoclonal antibodies to treat prostate cancer. Such combined treatment is particularly effective for patients with pelvic lymph node involvement, of which only 34% survive after 5 years .
- An example of such monoclonal antibodies is cell membrane- specific anti -prostate antibody.
- the present invention may also be used with immunotherapies based on polyclonal or monoclonal antibody- derived reagents .
- Monoclonal antibody-derived reagents are preferred. These reagents are well known in the art, and include radiolabelled monoclonal antibodies such as monoclonal antibodies conjugated with strontium-89. (v) Cryotherapy The methods of the present invention may also be used in conjunction with cryotherapy for treatment of prostate cancer.
- LNCAP cells a prostate cancer cell line
- quisqualate acid in concentrations ranging from 10 nM to 1 ⁇ M
- 2- (phosphonomethyl) pentanedioic acid in concentrations ranging from 100 pM to 10 nM
- FIGS. 1 and 2 present this data graphically and particularly illustrate the decrease in proliferation and thymidine uptake of cells treated with NAALADase inhibitors.
- the agents are simultaneously evaluated on a non-NAALADase containing prostate cell line, DU145 (Carter et al . , Proc .
- NAALADase inhibiting activity of the agents are uniquely responsible for their cytostatic effects on NAALADase containing prostate carcinoma cell lines.
- LNCAP cells are obtained from Dr. William Nelson at the Johns Hopkins School of Medicine in Baltimore, MD.
- DU145 cells are obtained from American Type Culture Collection (Rockville, MD) .
- Cells are grown in RPMI-1640 media supplemented with 10% heat-inactivated fetal calf serum, 2 mM- glutamine, 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin (Paragon) in a humidified incubator at 37°C in a 5% C0 2 /95% 0 2 atmosphere.
- the cells are suspended at 1 x 10 3 cells/ml in RPMI-1640 media and seeded into 24 -well plates at 500 ⁇ l per well. After 24 hours, various concentrations of quisqualic acid (Sigma) or the potent NAALADase inhibitor 2-
- LNCaP human prostate cancer cells were injected subcutaneously into the right flank of male nude mice.
- 2- (phosphonomethyl) pentanedioic acid a NAALADase inhibitor
- An additional group was included using a silicon polymer containing 2- (phosphonomethyl) pentanedioic acid which released approximately 0.25 ⁇ g/day of drug locally into the tumor.
- the 2- (phosphonomethyl) entanedioic acid polymer was changed two times per week. Tumor volumes were monitored for 42 days after the beginning of treatment.
- LNCaP is a human prostate cancer cell line that was established in 1973 from a pleural effusion of a patient who had been treated with 5-FU, doxorubicin, methotrexate, and CTX in the 3 months before the cell line was initiated. This line is androgen receptor positive and has been used in screening anticancer drugs that are targeted as hormone antagonists. LNCaP was grown in RPMI with 1.5 g NaHC03/L, 10% fetal bovine serum (FBS) , and 2 mM L-glutamine and was kept at 37°C in a humidified 5% C0 2 /0 2 incubator. Antibiotics were not added to the medium.
- FBS fetal bovine serum
- NCr nude (nu/nu) male mice age 4-5 weeks, were purchased from Taconic (Germantown, NY) .
- the animals were housed four per cage in sterile filter-topped cages in a ventilated cage rack. Upon arrival, they were quarantined for four working days before use. Temperature was maintained at 72 ⁇ 5°F and relative humidity at 35-70%, and a 12 -hr light/dark cycle is used.
- the mice were fed sterile, autoclavable, certified Purina rodent chow ad libi tum. Drinking water was acidified and autoclaved, and the source water was recirculated, deionized, UV-treated, and 5- ⁇ m filtered.
- 2- (phosphonomethyl) pentanedioic acid was made up in water at a concentration of 2.5 mg/ml .
- Polymer containing 2- (phosphonomethyl) pentanedioic acid was made up by grinding 140 mg NaCl to a fine powder then mixing with 5mg 2- (phosphonomethyl) pentanedioic acid and 350 mg silicone gel. The mixture was spread to a thin film and allowed to dry for 24 hours. The material was cut into 1-1.5 mg pieces for subcutaneous implantation.
- mice When the tumor volumes reached a predetermined size (mean tumor volume 50-70 mm 3 ) , mice were added randomly into treatment groups of six to eight mice each. All treatments were administered daily for at least 4 weeks. 2- (phosphonomethyl ) pentanedioic acid was administered intratumorally daily in a volume of 0.05 -ml containing 0..025 ⁇ g 2- (phosphonomethyl) pentanedioic acid per injection.
- Polymer containing 2- (phosphonomethyl) pentanedioic acid (10 ⁇ g drug/mg polymer) was implanted subcutaneously . Mice were anaesthetized with metafane, and a small ( ⁇ 2mm) incision was made near the tumor site. Following implantation, the incision was closed with a wound clip. Polymer was replaced twice weekly.
- the tumor were measured twice weekly for at least 8 weeks after the first treatment.
- the mean tumor volume for each group was calculated for each time point. Comparisons between groups at specific times were made using an unpaired, two-tailed t-test, and the results were analyzed using analysis of variance (ANOVA) .
- R3327-G is a cell line derived from an androgen-sensitive papillary adenocarcinoma derived from a spontaneously forming tumor in the rat prostate.
- R3327-G cells were grown in RPMI, 10% fetal bovine serum (FBS) , 2 mM L-glutamine, and 10-8 M dexamethasone . Cultures were kept at 37°C in a humidified 5% C0 2 /0 2 incubator. Antibiotics were not added to the medium.
- Copenhagen male rats age 8-10 weeks, were purchased from Harlan Sprague Dawley (Indianapolis, IN) . The animals were housed two per cage. Upon arrival, they were quarantined for four working days before use . Temperature was maintained at 72 + 5°F and relative humidity at 35-70%, and a 12-hr light/dark cycle was used. The rats were fed certified Purina rodent chow and water ad libi tum .
- 2- (phosphonomethyl) pentanedioic acid was made up in physiological saline fresh each day prior to injection.
- a stock solution of 2 - [ [pheny lme t hy 1 ) hydroxyphosphiny1 ] methyl] pentanedioic acid was made up in water at a concentration 2.5 mg/ml ; ten- fold serial dilutions were made fresh weekly for injections .
- the rats were given daily subcutaneous injections of drug beginning the 14 days following tumor cell implantation and continued for 12 weeks.
- the drug was not administered until the tumor volumes reached a predetermined size (mean tumor volume 90- 290 mm 3 ) .
- the rats were divided into treatment groups of five rats each. All treatments of 2- [ [phenylmethyl) hydroxyphosphinyl] methyl] pentanedioic acid were subsequently administered intra-tumorally daily for 6 weeks.
- the tumors were measured twice weekly. The mean tumor volume for each group was calculated for each time point. Comparisons between groups at specific times were made using an unpaired, two-tailed t-test, and the results were analyzed using analyzed of variance (ANOVA) .
- ANOVA analyzed of variance
- Butylphosphinic Acid Piethyl chlorophosphite (25g, 0.16mol) in 60 mL of dry ether was cooled to 0°C under an atmosphere of nitrogen. Butylmagnesium chloride (80 mL, 0.16 mol, 2.0 M solution in ether) was added dropwise over a period of 2 hours while maintaining the internal temperature at 0°C. Once addition was complete the thick white slurry was heated to 30°C for 1 hour. The suspension was filtered under a nitrogen atmosphere and the filtrate evaporated under reduced pressure. The clear light yellow liquid was then brought up in 15 mL of water and stirred at room temperature. Concentrated hydrochloric acid (0.5 mL) was then added and an exothermic reaction was observed.
- Butyl f2 , 4-di (benzyloxycarbonyl) butyl] phosphinic acid Butylphosphinic acid (2.0g, 16mmol) in 80 mL of dry dichloromethane was cooled to 0°C under an atmosphere of nitrogen. Triethylamine (6.7 g, 66 mmol) was added followed by trimethylsilyl chloride (58 mL, 58 mmol, 1.0 M in dichloromethane) . The mixture was stirred at 0°C for 10 minutes and dibenzyl 2-methylenepentanedioate (2) (6.4 g, 20 mmol) in 20 mL of dichloromethane was added.
- Piethylchlorophosphite 25 g, 0.16 mol in 100 mL of dry diethyl ether was cooled to 0°C under an atmosphere of nitrogen.
- Benzylmagnesium chloride 80 mL, 0.16 mol, 2.0 M solution in Et 2 0
- a thick white slurry formed and stirring was continued at room temperature for 1 hour.
- the mixture was filtered under a nitrogen atmosphere and the filtrate evaporated under reduced pressure to give a clear and colorless liquid.
- the liquid was stirred as 15 mL of water was added followed by 0.5ml concentrated hydrochloric acid.
- Benzyl ⁇ 2 , 4-di (benzyloxyxcarbonyl ) butyl 1 hosphinic acid Benzylphosphinic acid (2.3 g, 15 mmol) in 150 mL of dry dichloromethane was cooled to 0°C under a nitrogen atmosphere. Triethylamine (6.5 g, 65mmol) was added followed by trimethylsilyl chloride (5.8 g, 54 mmol) while the reaction temperature was maintained at 0°C. After 30 minutes dibenzyl 2-methylenepentanediote (2) in 20 mL of dichloromethane was added over 5 minutes. The reaction mixture was left to warm to room temperature and stirred overnigh .
- Pry phosphinic acid 100 g, 1.52 mol was dissolved in 100 ml of chloroform and treated with triethylamine (155 g, 1.52mol) .
- the mixture was evaporated and transferred to a three liter flask, containing 750 mL of chloroform. The solution was stirred by means of a mechanical stirrer and the flask cooled to 0°C.
- the clear solution was treated with triethylamine (277 g, 2.72 mol) followed by trimethylsilyl chloride (281 g, 2.58 mol) .
- dibenzyl 2-methylenepentanedioate (2) in 150 mL of chloroform was added dropwise over 20 minutes. .
- the -low temperature bath was removed and the mixture warmed to room temperature.
- the thick slurry was filtered and the filtrate cooled to 0°C.
- the filtrate was then quenched with 5% hydrochloric acid and the organic layer removed.
- the aqueous layer was extracted with chloroform, the organics combined, dried (MgS0 4 ) and evaporated under reduced pressure to give 55 g of 2 , 4-di (benzyloxycarbonyl) butylphosphinic acid (6) as a light yellow liquid.
- a patient is diagnosed with adenocarcinoma of the prostate.
- the patient may then be administered a NAALADase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor.
- the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by subdural pump. It would be expected that no further occurrences of the adenocarcinoma would develop.
- EXAMPLE 16 A patient is diagnosed with adenocarcinoma of the prostate. The patient may then be administered a NAALADase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor. After this initial treat ent, the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by implantation of a biocompatible, polymeric matrix delivery system. It would be expected that no further occurrences of the adenocarcinoma would develop.
- a NAALADase inhibitor such as set forth in examples 1 through 3
- EXAMPLE 17 A patient is diagnosed with benign prostatic hyperplasia. The patient may then be administered a NAALADase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor. After this initial treatment, the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by injection, subdural pump, or polymeric matrix implant. It would be expected that the benign prostatic hyperplastic cells do not develop into carcinoma.
- a NAALADase inhibitor such as set forth in examples 1 through 3
- the patient may be optionally administered the same or different NAALADase inhibitor by intermittent or continuous administration by injection, subdural pump, or polymeric matrix implant. It would be expected that the benign prostatic hyperplastic cells do not develop into carcinoma.
- EXAMPLE 18 A patient is diagnosed with adenocarcinoma of the prostate. The adenocarcinoma appears not to have metastasized. The adenocarcinoma would be removed by surgery. After pos -operative recovery, the patient would be locally administered NAALADase inhibitor by intermittent or continuous administration by injection, subdural pump or by polymeric matrix implant. It would expected that no further occurrences of the carcinoma would develop. EXAMPLE 19
- a patient is diagnosed with metastatic adenocarcinoma of the prostate .
- the adenocarcinoma appears to have metastasized, but surgery still is indicated as an effective treatment modality.
- Tumor tissue would be removed by surgery.
- the patient would be locally administered a NAALADase inhibitor such as described herein from the time, approximately, of the initial diagnosis and would continue after surgery. After post-operative recovery, the patient would be maintained at this level of NAALADase inhibitor by a regimen of periodic local administration.
- the patient would be monitored carefully for intolerable adverse side-effects of NAALADase inhibitor administration. It would be expected that no further tumors develop. If some of the original, small tumorous masses are detected after surgery, they would be expected to not grow in size.
- EXAMPLE 20 A patient is diagnosed with ACTH- roducing tumors. The patient may then be administered a NAALAPase inhibitor, such as set forth in examples 1 through 3, by direct injection into the tumor. After this initial treatment, the patient may be optionally administered the same or different NAALAPase inhibitor by direct injection, subdural pump, or implantation of a biocompatible, polymeric matrix delivery system. It would be expected that tumor growth or tumor cell growth would be prevented or inhibited and that no further occurrences of the ACTH-producing tumor would develop.
- a NAALAPase inhibitor such as set forth in examples 1 through 3
- EXAMPLE 21 A treatment such as that described in Example 9 wherein the patient is diagnosed with acute lymphocytic leukemia.
- EXAMPLE 22 A treatment such as that described in Example 9 wherein the patient is diagnosed with acute non-lymphocytic leukemia.
- EXAMPLE 23 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cancer of the adrenal cortex.
- EXAMPLE 24 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic bladder cancer.
- EXAMPLE 25 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic brain cancer.
- EXAMPLE 26 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic brain cancer.
- EXAMPLE 27 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cervical cancer.
- EXAMPLE 28 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic chronic lymphocytic leukemia.
- EXAMPLE 29 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic chronic myelocytic leukemia.
- EXAMPLE 30 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic colorectal cancer.
- EXAMPLE 31 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cutaneous T-cell lymphoma.
- EXAMPLE 32 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic endometrial cancer.
- EXAMPLE 33 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic endometrial cancer.
- EXAMPLE 34 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Ewing's sarcoma.
- EXAMPLE 35 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic gallbladder cancer.
- EXAMPLE 36 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic hairy cell leukemia.
- EXAMPLE 37 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic head and neck cancer.
- EXAMPLE 38 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Hodgkin' s lymphoma.
- EXAMPLE 39 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Kaposi's sarcoma.
- EXAMPLE 40 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic Kaposi's sarcoma.
- EXAMPLE 41 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic liver cancer.
- EXAMPLE 42 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic lung cancer (small cell and/or non-small cell) .
- EXAMPLE 43 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic malignant peritoneal effusion.
- EXAMPLE 44 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic malignant pleural effusion.
- EXAMPLE 45 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic melanoma.
- EXAMPLE 46 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic mesothelioma .
- EXAMPLE 47 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic multiple myeloma.
- EXAMPLE 48 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic multiple myeloma.
- EXAMPLE 49 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic non-Hodgkin' s lymphoma.
- EXAMPLE 50 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic osteosarcoma.
- EXAMPLE 51 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic ovarian cancer (and/or germ cell ovarian cancer) .
- EXAMPLE 52 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic pancreatic cancer.
- EXAMPLE 53 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic penis cancer.
- EXAMPLE 54 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic retinoblastom .
- EXAMPLE 55 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic skin cancer.
- EXAMPLE 56 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic skin cancer.
- Example 9 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic soft-tissue sarcoma.
- EXAMPLE 57 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic squamous cell carcinoma.
- EXAMPLE 58 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic squamous cell carcinoma.
- EXAMPLE 59 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic testicular cancer.
- EXAMPLE 60 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic thyroid cancer.
- EXAMPLE 61 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic trophoblastic neoplasm.
- EXAMPLE 62 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic uterine cancer.
- EXAMPLE 63 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic uterine cancer.
- EXAMPLE 64 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cancer of the vulva.
- EXAMPLE 65 A treatment such as that described in Example 9 wherein the patient is diagnosed with metastatic or non-metastatic cancer of the vulva.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97937265A EP0994707A4 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
JP50191298A JP2002514158A (en) | 1997-05-27 | 1997-08-15 | Inhibitors of NAALADase enzyme activity |
CA002291258A CA2291258A1 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
AU39821/97A AU739443B2 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/863,624 US6046180A (en) | 1996-06-17 | 1997-05-27 | NAALADase inhibitors |
US08/863,624 | 1997-05-27 | ||
US08/858,985 US6025344A (en) | 1996-06-17 | 1997-05-27 | Certain dioic acid derivatives useful as NAALADase inhibitors |
US08/858,985 | 1997-05-27 | ||
US08/864,545 US6011021A (en) | 1996-06-17 | 1997-05-28 | Methods of cancer treatment using naaladase inhibitors |
US08/864,545 | 1997-05-28 | ||
US08/900,194 US6025345A (en) | 1996-06-17 | 1997-07-25 | Inhibitors of NAALADase enzyme activity |
US08/900,194 | 1997-07-25 | ||
ZA977087A ZA977087B (en) | 1996-06-17 | 1997-08-08 | Methods of cancer treatment using naaladase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998053812A1 true WO1998053812A1 (en) | 1998-12-03 |
Family
ID=27542266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/014347 WO1998053812A1 (en) | 1997-05-27 | 1997-08-15 | Inhibitors of naaladase enzyme activity |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0994707A4 (en) |
WO (1) | WO1998053812A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038785A2 (en) * | 1998-12-31 | 2000-07-06 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
WO2001034596A2 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
EP1212055A1 (en) * | 1999-08-16 | 2002-06-12 | Revaax Pharmaceuticals LLC | Neurotherapeutic composition and method |
US6586623B2 (en) * | 2001-01-17 | 2003-07-01 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
WO2006054182A2 (en) * | 2004-09-16 | 2006-05-26 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as hiv inhibitors |
DE102006010362A1 (en) * | 2006-03-07 | 2007-09-13 | Clariant International Limited | Mixtures of mono-carboxyl-functionalized dialkylphosphinic acids, a process for their preparation and their use |
US7399461B2 (en) | 1993-11-05 | 2008-07-15 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US7960428B2 (en) | 2006-09-29 | 2011-06-14 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as HIV inhibitors |
WO2011073286A1 (en) | 2009-12-18 | 2011-06-23 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
CN101084231B (en) * | 2004-09-17 | 2011-08-24 | 埃迪尼克斯医药公司 | Phosphoindoles as HIV inhibitors |
US8008325B2 (en) | 2002-03-21 | 2011-08-30 | Bayer Schering Pharma Ag | Plasma carboxypeptidase B inhibitors |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
USRE43586E1 (en) | 1992-11-05 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
EP2567696A1 (en) | 2006-11-22 | 2013-03-13 | Seaside Therapeutics, Inc. | Compositions for treating autism spectrum disorder |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4602092A (en) * | 1983-09-19 | 1986-07-22 | E. R. Squibb & Sons, Inc. | Method for making phosphinic acid intermediates |
US4988681A (en) * | 1988-06-23 | 1991-01-29 | Banyu Pharmaceutical Co., Ltd. | Phosphinic acid derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5500420A (en) * | 1993-12-20 | 1996-03-19 | Cornell Research Foundation, Inc. | Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia |
ID18382A (en) * | 1996-09-27 | 1998-04-02 | Guilford Pharm Inc | PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT OF COMPULSIF DISORDERS USING NAALADASE INHIBITORS |
-
1997
- 1997-08-15 EP EP97937265A patent/EP0994707A4/en not_active Withdrawn
- 1997-08-15 WO PCT/US1997/014347 patent/WO1998053812A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4602092A (en) * | 1983-09-19 | 1986-07-22 | E. R. Squibb & Sons, Inc. | Method for making phosphinic acid intermediates |
US4988681A (en) * | 1988-06-23 | 1991-01-29 | Banyu Pharmaceutical Co., Ltd. | Phosphinic acid derivatives |
Non-Patent Citations (2)
Title |
---|
JACKSON P. F., ET AL.: "DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY OF A POTENT INHIBITOR OF THE NEUROPEPTIDASE N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE.", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39., no. 02., 19 January 1996 (1996-01-19), US, pages 619 - 622., XP002072189, ISSN: 0022-2623, DOI: 10.1021/jm950801q * |
See also references of EP0994707A4 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43586E1 (en) | 1992-11-05 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US7399461B2 (en) | 1993-11-05 | 2008-07-15 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
WO2000038785A3 (en) * | 1998-12-31 | 2000-09-21 | Guilford Pharm Inc | Methods for treating certain diseases using naaladase inhibitors |
WO2000038785A2 (en) * | 1998-12-31 | 2000-07-06 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US6806261B2 (en) | 1998-12-31 | 2004-10-19 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
EP1371367A1 (en) * | 1998-12-31 | 2003-12-17 | Guilford Pharmaceuticals Inc. | Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases |
EP1212055A1 (en) * | 1999-08-16 | 2002-06-12 | Revaax Pharmaceuticals LLC | Neurotherapeutic composition and method |
US7842683B2 (en) | 1999-08-16 | 2010-11-30 | Revaax Pharmaceuticals, Llc | Neurotherapeutic compositions and method |
EP1212055A4 (en) * | 1999-08-16 | 2005-09-07 | Revaax Pharmaceuticals Llc | Neurotherapeutic composition and method |
WO2001034596A3 (en) * | 1999-11-12 | 2002-03-07 | Guilford Pharm Inc | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
WO2001034596A2 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
WO2001092273A3 (en) * | 2000-05-30 | 2002-07-25 | Guilford Pharm Inc | Benzenedicarboxylic acid derivatives |
WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
US6812364B2 (en) | 2001-01-17 | 2004-11-02 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US6992215B2 (en) | 2001-01-17 | 2006-01-31 | Guildford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US6586623B2 (en) * | 2001-01-17 | 2003-07-01 | Guilford Pharmaceuticals Inc. | Thiol-based NAALADase inhibitors |
US9695248B2 (en) | 2001-10-23 | 2017-07-04 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
US8008325B2 (en) | 2002-03-21 | 2011-08-30 | Bayer Schering Pharma Ag | Plasma carboxypeptidase B inhibitors |
WO2006054182A2 (en) * | 2004-09-16 | 2006-05-26 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as hiv inhibitors |
US7534809B2 (en) | 2004-09-17 | 2009-05-19 | Idenix Pharmaceuticals, Inc. | Phospho-indoles as HIV inhibitors |
US8044091B2 (en) | 2004-09-17 | 2011-10-25 | Idenix Pharmaceuticals, Inc. | Phospho-indoles as HIV inhibitors |
WO2006054182A3 (en) * | 2004-09-17 | 2007-03-01 | Idenix Pharmaceuticals Inc | Phosphoindoles as hiv inhibitors |
CN101084231B (en) * | 2004-09-17 | 2011-08-24 | 埃迪尼克斯医药公司 | Phosphoindoles as HIV inhibitors |
AU2005305609B2 (en) * | 2004-09-17 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Phosphoindoles as HIV inhibitors |
US8097753B2 (en) | 2006-03-07 | 2012-01-17 | Clariant Finance (Bvi) Limited | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation |
DE102006010362A1 (en) * | 2006-03-07 | 2007-09-13 | Clariant International Limited | Mixtures of mono-carboxyl-functionalized dialkylphosphinic acids, a process for their preparation and their use |
US7960428B2 (en) | 2006-09-29 | 2011-06-14 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as HIV inhibitors |
US8486991B2 (en) | 2006-09-29 | 2013-07-16 | Idenix Pharmaceuticals, Inc. | Enantiomerically pure phosphoindoles as HIV inhibitors |
EP2567696A1 (en) | 2006-11-22 | 2013-03-13 | Seaside Therapeutics, Inc. | Compositions for treating autism spectrum disorder |
EP2578216A1 (en) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Methods of treating fragile x syndrome |
WO2011073286A1 (en) | 2009-12-18 | 2011-06-23 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
EP2338892A1 (en) | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostate specific membrane antigen inhibitors |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
Also Published As
Publication number | Publication date |
---|---|
EP0994707A1 (en) | 2000-04-26 |
EP0994707A4 (en) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6046180A (en) | NAALADase inhibitors | |
US6011021A (en) | Methods of cancer treatment using naaladase inhibitors | |
US6025344A (en) | Certain dioic acid derivatives useful as NAALADase inhibitors | |
US5804602A (en) | Methods of cancer treatment using naaladase inhibitors | |
US5968915A (en) | Naaladase inhibitors | |
US6025345A (en) | Inhibitors of NAALADase enzyme activity | |
US5863536A (en) | Phosphoramidate derivatives | |
US5795877A (en) | Inhibitors of NAALADase enzyme activity | |
US6054444A (en) | Phosphonic acid derivatives | |
EP0994707A1 (en) | Inhibitors of naaladase enzyme activity | |
US6372726B1 (en) | Methods of cancer treatment using NAALADase inhibitors | |
JP2001527084A (en) | Prodrugs of NAALDase inhibitors | |
WO1999033847A1 (en) | Phosphinic alkanoic acid derivatives | |
AU739443B2 (en) | Inhibitors of naaladase enzyme activity | |
CZ390198A3 (en) | Use of NAALADase inhibitor when preparing medicament for treating cancer, suppression of tumor cell growth or disorder relating to NAALADase enzyme activity in animal | |
MXPA00006283A (en) | Prodrugs of naaladase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997937265 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2291258 Country of ref document: CA Ref country code: CA Ref document number: 2291258 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997937265 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997937265 Country of ref document: EP |